Open Access

Cytotoxic compounds from Laurencia pacifica

  • Diana A Zaleta-Pinet1,
  • Ian P Holland1,
  • Mauricio Muñoz-Ochoa2,
  • J Ivan Murillo-Alvarez2,
  • Jennette A Sakoff3,
  • Ian A van Altena1 and
  • Adam McCluskey1Email author
Organic and Medicinal Chemistry Letters20144:8

DOI: 10.1186/s13588-014-0008-8

Received: 3 June 2014

Accepted: 17 August 2014

Published: 20 September 2014

Abstract

Background

The current investigation sought to explore the nature of the secondary metabolites in the algae, Laurencia pacifica.

Results

This report details the first isolation of the sesquiterpenes isoaplysin (1), isolaurenisol (2), debromoisolaurinterol (3), debromoaplysinol (4), laur-11-en-10-ol (5), 10α-hydroxyldebromoepiaplysin (6), and the previously unknown 10-bromo-3,7,11,11-tetramethylspiro[5.5]undeca-1,7-dien-3-ol (7) from the algae, Laurencia pacifica. Isoaplysin (1) and debromoaplysinol (4) showed promising levels of growth inhibition against a panel cancer-derived cell lines of colon (HT29), glioblastoma (U87, SJ-G2), breast (MCF-7), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), pancreas (MIA), murine glioblastoma (SMA) origin with average GI50 values of 23 and 14 μM.

Conclusions

Isoaplysin (1) and debromoaplysinol (4) were up to fourfold more potent in cancer-derived cell populations than in non-tumor-derived normal cells (MCF10A). These analogues are promising candidates for anticancer drug development.

Keywords

Laurencia pacifica Algae Sesquiterpenes Anti-cancer Cytotoxicity

Findings

Introduction

Natural products with their high fraction sp 3 content (Fsp3) represent a significant proportion of all clinical drugs [1]. Of the 1,355 new entities introduced as therapeutics between 1981 and 2010, 71% were natural products or natural product derived [2]. A high Fsp3 content imbues natural products with defined three-dimensional geometry that allows for high levels of interaction with a wide range of biological targets. A significant number of natural products adhere to the `rule of five´ and thus present high levels of drug-like character [3],[4]. Natural products also afford access to a wide range of novel chemical motifs accessing new chemical space in the drug design and development arena. This has led to the ongoing interest in accessing natural product secondary metabolites (in particular) with their high chemical diversity and biological specificity, making them a favorable source of lead compounds for drug discovery and development [5],[6].

Recently, we turned our attention to marine natural products as a potential source for new lead compounds. In this area, we have identified a small family of cytotoxic steroids from an Australian sponge Psammoclema sp. [7], and antimalarial, antialgal, antitubercular, antibacterial, antiphotosynthetic, and antifouling activity of diterpene and diterpene isonitriles from the tropical marine sponge Cymbastela hooperi[8]. In this present study, we examined the cytotoxicity of extracts obtained from Laurencia pacifica algae collected in the pacific coast of the Baja California Peninsula, Mexico.

The genus Laurencia typically inhabits the world's tropical oceans and has been responsible for approximately half of all the reported compounds from red algae. This genus is considered an important producer of halogenated sesquiterpenes, diterpenes, and acetogenins [9]-[11]. Biological activities of the Laurencia family range from antipredatory [12], antifungal [13], antibacterial [14]-[16], to anticancer [17]-[19]. Secondary metabolites reported from L. pacifica include γ-bisabolene, bromocuparane, laurinterol, debromolauriterol, isolaurinterol, aplysin, debromoaplysin, 10-bromo-α-chamigrene, prepacifenol, pacifenol, pacifidine, and kylinone [10].

Results and discussion

The algae, L. pacifica was collected from the Baja California Peninsula, Mexico. The ethanol extracts were examined for the potential presence of cytotoxic compounds. Cytotoxicity screening was conducted against a panel of cancer cell lines of colon (HT29), glioblastoma (U87, SJ-G2), breast (MCF-7), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), pancreas (MIA), murine glioblastoma (SMA) origin, and a normal line of breast cells (MCF10A) [20]. The preliminary screening showed sufficient promise to embark on an isolation program (data not shown).

Bioassay-guided fractionation (normal phase chromatography) of the L. pacifica ethanolic extracts (see Additional file 1) resulted in the isolation of seven sesquiterpenes: isoaplysin (1) [21],[22], isolaurenisol (2) [13],[22], debromoisolaurinterol (3) [23], debromoaplysinol (4) [10],[13],[21], laur-11-en-10-ol (5) [13], 10α-hydroxyldebromoepiaplysin (6) [13] (Figure 1) and the previously unreported 10-bromo-1,7-dien-3-ol (7) (Figure 2). Sesquiterpenes 1 to 6 were identified in comparison with their spectroscopic data against literature data [21]-[23].
Figure 1

Chemical structures of the known sesquiterpenes isolated from Laurencia pacifica in this work. Isoaplysin (1), isolaurenisol (2), debromoisolaurinterol (3), debromoaplysinol (4), laur-11-en-10-ol (5), and 10α-hydroxyldebromoepiaplysin (6).

Figure 2

Important HMBC (blue arrows) and COSY (bold bonds) correlations for 7, and the chemical structure of the related 10-bromo-7,8-epoxychamigr-1-en-3-ol (8).

Sesquiterpenes 1 to 6 have been found in other Laurencia algae: L. okumurai, (1, 2, 3, 4, and 6) [21],[22], L. gracilis (2) [24],[25], L. tristicha (5) [19], and L. distichophylla (3) [26]. This work represents the first identification of these sequiterpenes in L. pacifica.

Sesquiterpene 7 was isolated in very small quantities (approximately 100 ng) from 2 kg of algae and was identified through a combination of high resolution mass spectrometry, infrared spectroscopy, and heteronuclear multiple bond correlation (HMBC), heteronuclear single quantum correlation (HSQC), correlated spectroscopy (COSY) NMR (see Additional file 1). The spectral data obtained closely matched reported spectral data of the related 10-bromo-7,8-expoxychamigr-1-en-3-ol (8) (Figure 2) [26], in which the C6 stereochemistry was determined by detailed NMR analysis and was consistent with our data [27]-[29]. The peak assignment and spectral comparison of 7 and 8 are shown in Table 1. There are three related structures with the C1-C2 double bond, one of which is supported by crystal structure data and is of the same absolute configuration as shown for 7 and 8. While these data are wholly consistent with our assignment, Suescun et al. have identified another compound with the opposite C6 configuration [29]. We thus consider our absolute configuration assignment as tentative. Notwithstanding this, the spectroscopic data is consistent with the assigned structure and represents a new sesquiterpene from L. pacifica (Figure 2).
Table 1

1D and 2D NMR spectroscopic data (and assignments) obtained from sesquiterpene 7 and 1D NMR data for 10-bromo-7,8-expoxychamigr-1-en-3-ol (8)[26]

Position

δC,a typeb

δH(H, multi, J Hz)

1H- 1H COSY

HMBC

δCc

δH (multi, J Hz)

1

136.4, CH

5.84 (1H, d, 10.4)

2

6

136.1

5.84 (dd, 10.4, 1.0)

2

131.1, CH

5.53 (1H, d, 10.4)

1

3, 6, 15

131.3

5.73 (dd, 10.4, 1.6)

3

67.5, q C

-

-

-

66.8

-

4

36.1, CH2

1.80 (1H, m), 1.73 (1H, m)

5

3

35.0

1.79 (m), 1.81 (m)

5

28.2, CH2

1.98 (2H, m)

4

3, 6

23.1

1.69 (ddd, 13.2, 11.2, 4.7), 1.94 (d, 13.2)

6

48.0, q C

-

-

-

45.9

-

7

139.0, q C

-

-

-

60.5

-

8

120.2, CH

5.22 (1H, s)

9, 14

-

61.4

2.97 (d, 3.0)

9

35.8, CH2

2.78 (1H, m), 2.56 (1H, m)

8, 10

-

35.1

2.40 (ddd, 15.4, 11.4, 3.0), 2.69 (dd, 15.4, 5.8)

10

62.0, CH

4.63 (1H, dd, 10.8, 6.3)

9b

12

58.4

4.28 (dd, 11.4, 5.8)

11

41.5, q C

-

-

-

40.0

-

12

17.8, CH3

1.01 (3H, s)

13

13

18.2

1.08 (s)

13

26.1, CH3

1.10 (3H, s)

12

6, 10, 12

25.8

0.98 (s)

14

21.7, CH3

1.55 (3H, s)

9

 

26.0

1.17 (s)

15

28.6, CH3

1.29 (3H, bs)

-

 

29.3

1.33 (s)

aData recorded in CDCl3 calibrated at δH 7.24 ppm an for δc 77.0 for residual solvent; bin the case of a diasterotopic pair of hydrogens, `a´ denotes the downfield proton while `b´ denotes the up field proton; cchemical shift for the carbons was inferred from HSQC and HMBC data.

Sequiterpenes 1 to 5 were isolated in sufficient quantities allowing direct evaluation as pure compounds against a panel of cancer and non-cancer-derived cell lines. Due to the low levels of sesquiterpenes 6 and 7, these were screened as a 1:1 mixture (both were isolated from the same extract fraction as determined by 1H NMR) [30]. Initial cytotoxicity screening was conducted at a single dose of 25 μM, and these data are presented in Table 2.
Table 2

Percentage growth inhibition by sesquiterpenes (1 to 7)

 

Compound

Cell line

1

2

3

4

5

6/7

HT29a

60 ± 3

12 ± 2

12 ± 5

>100

<10

10 ± 5

U87b

25 ± 2

13 ± 6

15 ± 7

52 ± 2

12 ± 4

15 ± 6

MCF-7c

81 ± 6

<10

<10

>100

<10

<10

A2780d

65 ± 5

<10

<10

99 ± 1

<10

<10

H460e

11 ± 1

<10

<10

71 ± 1

<10

<10

A431f

86 ± 1

<10

<10

>100

<10

<10

Du145g

41 ± 1

23 ± 6

18 ± 3

92 ± 2

18 ± 2

17 ± 3

BE2-Ch

>100

<10

<10

>100

<10

<10

SJ-G2b

40 ± 5

<10

10 ± 3

>100

12 ± 3

14 ± 3

MIAi

47 ± 2

12 ± 4

17 ± 3

92 ± 2

18 ± 3

19 ± 2

SMAj

34 ± 8

<10

<10

95 ± 1

<10

<10

MCF10Ak

10 ± 6

<10

<10

31 ± 10

<10

<10

Isoaplysin (1), isolaurenisol (2), debromoisolaurinterol (3), debromoaplysinol (4), laur-11-en-10-ol (5), and a 1:1 mixture of the 3α-hydroxydebromoaplysin (6) and 10-bromo-1,7-dien-3-ol (7) against a panel of cancer and non-cancer derived cell lines at a single dose (25 μM). Values are measured relative to an untreated control. aColon; bglioblastoma; cbreast; dovarian; elung; fskin; gprostate; hneuroblastoma; ipancreas; jglioblastoma (murine); kbreast (normal).

Analysis of the cytotoxicity data presented in Table 2 highlights the low level of cell death of the 12 cell lines examined on treatment with 2, 3, 5, and 6/7. Isoaplysin (1) and debromoaplysinol (4) displayed promising levels of cell death from 10% to >100% and 31% to >100% at 25 μM drug concentration, respectively. Of the other analogues, only isolaurenisol (2) displayed any growth inhibition at >20% (Du145, prostate cancer cell line). Given the activities of these three analogues, a full dose response evaluation was undertaken across our panel of carcinoma and normal cell lines [20]. These data are presented in Table 3.
Table 3

Growth inhibition (GI 50 μM) of isoaplysin (1), isolaurenisol (2), and debromoaplysinol (4) against a panel of cancer and non-cancer derived cell lines

 

Compound

Cell line

1

2

4

HT29a

15 ± 1.2

>50

9.1 ± 1.1

U87b

40 ± 0.6

>50

26 ± 1.7

MCF-7c

20 ± 1.3

>50

14 ± 1.7

A2780d

17 ± 0.6

>50

10 ± 1.7

H460e

34 ± 1.2

>50

18 ± 0.3

A431f

17 ± 0.6

>50

9.6 ± 0.9

Du145g

12 ± 0.3

>50

6.8 ± 0.3

BE2-Ch

27 ± 2.3

>50

13 ± 0.9

SJ-G2b

29 ± 0.7

>50

15 ± 0.7

MIAi

23 ± 1.5

>50

16 ± 0.7

SMAj

24 ± 3.8

>50

14 ± 1.2

MCF10Ak

46 ± 3.2

>50

28 ± 1.0

GI50 is the concentration of drug that reduces cell growth by 50%. aColon; bglioblastoma; cbreast; dovarian; elung; fskin; gprostate; hneuroblastoma; ipancreas; jglioblastoma (murine); kbreast (normal).

As anticipated, isolaurenisol (2) displayed no noteworthy cytotoxicity returning a GI50 value > 50 μM across all cell lines examined. Both isoaplysin (1) and debromoaplysinol (4) displayed good to excellent levels of cytotoxicity. Isoaplysin (1) returned an average GI50 value of 23 μM (from 15 ± 1.2 μM to 40 ± 0.6 μM against the HT29 and U87 cell lines, respectively), while debromoaplysinol (4) returned an average GI50 value of 14 μM (from 6.8 ± 0.3 μM to 26 ± 1.7 μM against the Du145 and U87 cell lines, respectively) when screened in cancer-derived cell lines. Both compounds showed the greatest growth inhibitory effect in the prostate cancer-derived cell line Du145 with GI50 values of 12 and 6.8 μM, respectively, and the least growth inhibitory effect in the non-cancer-derived normal breast cells with GI50 values of 46 and 28 μM, respectively. Indeed, 1 and 4 were up to fourfold more potent in cancer-derived cell populations than normal cells, imbuing them with properties favorable for future development as anti-cancer agents.

Given the structural similarity of the isolated analogues (1 to 6), being direct structural homologues or biosynthetically related, the observed differences in cytotoxicity suggest that the presence of the furan moiety and positioning and nature of the pendent substituents was important for cytotoxicity. Analogues 1 and 4 are Br − OH bioisosteres, and 4 and 6 are positional isomers (C3a-OH (1) and a C10a-OH (6)). The position of the − OH moiety is clearly important with the 3α-hydroxydebromoaplysin (6) devoid of cytotoxicity, whereas debromoaplysinol (4) displays excellent levels of activity (for a potential lead compound) against the HT29 (9.1 μM), A431 (9.6 μM), and Du145 (6.8 μM) cell lines [31]. Isoaplysin (1) and debromoaplysinol (4) differ only in the presence of the C3a-Br (1) and a C3a-OH (4) moiety, and 4 displays enhanced specific and broad spectrum cytotoxicity relative to 1, suggesting that the − OH moiety enhances the cytotoxicity of this class of compounds.

Sun et al. isolated and screened the related sesquiterpenes: aplysin-9-ene, epiaplysinol, debromoepiaplysinol, aplysinol, and aplysin isolated from Laurencia tristicha in a MTT assay against lung adenocarcinoma (A549), stomach cancer (BGC-823), hepatoma (Bel 7402), colon cancer (HCT-8), and HeLa cell lines [19]. Interestingly, only debromoepiaplysinol (epi-4, this work) displayed cytotoxicity with a GI50 = 15.5 μM against HeLa cells, where as herein, debromoaplysinol (4) displays activity across our panel of 11 cancer cell lines with strong activity in the HT29 (9.1 μM), A431 (9.6 μM), and Du145 (6.8 μM) cells [19]. These findings serve to emphasize the subtle nature of drug-ligand interactions and the role of stereochemistry in eliciting biological activity, c.f. 1, 4, and 6.

Conclusions

Herein, we have identified sesquiterpenes 1 to 6 for the first time in L. pacifica and isolated a new sesquiterpene and 10-bromo-1,7-dien-3-ol (7). Screening of these analogues against 11 cancer cell lines revealed modest to good levels of cytotoxicity for 1 and 4, with up to fourfold selectivity towards cancer-derived cell populations compared with normal cells. Given the low molecular weights and high Fsp3 content, the structure activity data elucidated in this small subset of analogues, we believe that 1 and 4 represent excellent leads for the development of selective and potent anticancer agents [31].

Experimental

General experimental

Solvents. Solvents used for TLC, speedy column, and centrifugal chromatography were of bulk quality and were distilled from glass prior to use. In the case of HPLC, all of the solvents were HPLC grade and were filtered and degassed prior to their use. The solvent referred as LP (light petroleum), is a mixture of different alkanes with a boiling point 60°C to 80°C.

Collection of the Mexican algae

L. pacifica algae were collected on the coast of the Baja California Peninsula, Mexico. The algae was cleaned of epiphytes, rinsed with fresh water, and dried in the sun at the collection site. The specimens were stored at −20°C. A voucher specimen of L. pacifica was preserved on location in 5% formaldehyde and deposited in a private collection at the Algal Laboratory in the Interdisciplinary Center of Marine Sciences (CICIMAR), La Paz, B.C.S., Mexico, for taxonomical identification and future reference. Subsequently, in the laboratory, 10 g of dry algae was roughly torn or cut to small pieces and then ground with a mortar and pestle. The powdered algae was then submerged in 250 mL of ethanol. The mixture was left for 48 h at 25°C to 35°C. Afterwards, the mixture was filtered and the residual algal tissue was extracted again under the same conditions. Both filtered extracts were combined and concentrated to dryness under reduced pressure at 40°C to obtain ca 30 mg of extract. These extracts were used for biological screening.

Extracts of L. pacifica and its fractionation

Crude extract of L. pacifica 2 kg of algae was reduced to small pieces of ca as before, and then submerged in 1 L of ethanol. The resulting mixture was left for 48 h at 25°C to 35°C. Afterwards, the mixture was filtered and the residual algal tissue was extracted again under the same conditions. Both filtered extracts were combined and concentrated to dryness under reduced pressure at 40°C to obtain 2.2 g of extract. Fractionation of the crude extract was commenced with a speedy column resulting in 18 fractions [32]. All fractions were tested in the colorimetric assay; active fractions were then fractionated in normal phase HPLC until isolation of a pure compound.

NMR

Proton and 13C NMR spectra were recorded on a Bruker Ascend 400 or Bruker Ascend 600 (Madison, WI, USA). All NMR spectra were recorded as CDCl3 solutions; the solvent signal was used as internal standard for chemical shifts (13C δ 77.0 ppm, and 1H δ 7.24 ppm for the residual CHCl3 proton). All spectra, including HSQC, HMBC, distortionless enhancement by polarization transfer (DEPT135), distortionless enhancement by polarization transfer with retention of quaternaries (DEPTQ135), and (homonuclear) COSY-utilized standard Bruker pulse programs.

Cell culture and stock solutions

Stock solutions were prepared as follows and stored at −20°C: drugs were stored as 20 mM solutions in DMSO. All cell lines were cultured at 37°C, under 5% CO2 in air. All cancer-derived cells lines were maintained in Dulbecco's modified Eagle's medium (Trace Biosciences, Sydney, Australia) supplemented with 10% fetal bovine serum, 10 mM sodium bicarbonate, penicillin (100 IU/mL), streptomycin (100 μg/mL), and glutamine (4 mM). The non-cancer-derived breast cell line MCF10A was maintained in Dulbecco's modified Eagle's medium and Ham's F12 medium (1:1, Trace Biosciences, Sydney, Australia) supplemented with 5% heat inactivated horse serum, HEPES (20 mM), penicillin (100 IU/ml), streptomycin (100 μg/mL), glutamine (2 mM), epidermal growth factor (20 ng/ml), hydrocortisone (500 mg/ml), cholera toxin (100 ng/ml), and insulin (10 μg/mL).

In vitro growth inhibition assay

Cells in logarithmic growth were transferred to 96-well plates. Cytotoxicity was determined by plating cells in duplicate in 100 mL medium at a density of 2,500 to 4,000 cells/well. On day 0, (24 h after plating) when the cells were in logarithmic growth, 100 μL medium with or without the test agent was added to each well. After 72 h, drug exposure growth inhibitory effects were evaluated using the MTT (3-[4,5-dimethyltiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay and absorbance read at 540 nm. Percentage growth inhibition was determined at a fixed drug concentration of 25 μM. A value of 100% is indicative of total cell growth inhibition. Those analogues showing appreciable percentage growth inhibition underwent further dose response analysis allowing for the calculation of a GI50 value. This value is the drug concentration at which cell growth is 50% inhibited based on the difference between the optical density values on day 0 and those at the end of drug exposure [20].

Isoaplysin: (3S,3aS,8bS)-3a-(Bromomethyl)-3,6,8b-trimethyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan ( 1 )

Isolated as a white powder: 1.5 mg; [α] D 20 = −5.3° (c 0.001, CH3OH); IRνmax 2,927 (C−H), 2,858, 1,620 (C = C), 1,593 (C = C), 1,499, 1,453 (C = C), 1,423, 1,376 (C−H), 1,268 (C−O), 1,135, 946 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.88 (d, J = 7.6 Hz, 1H, H-5), 6.66 (dd, J = 7.5, 0.7 Hz, 1H, H-4), 6.58 (s, 1H, H-2), 3.66, 3.56 (ABq, JAB = 11.1 Hz, 2H, H-12), 2.27 (s, 3H, H-15), 2.21 to 2.12 (m, 1H, H-10), 1.90 to 1.83 (m, 1H, H-8a), 1.70 to 1.60 (m, 2H, H-8b, H-9a), 1.50 (s, 3H, H-14), 1.20 to 1.13 (m, 1H, H-9b), 1.10 (d, J = 6.7 Hz, 3H, H-13). 13C NMR (101 MHz, CDCl3) δ 158.8 (q C, C-1), 138.3 (q C, C-3), 133.0 (q C, C-6), 122.2 (CH, C-5), 121.4 (CH, C-4), 109.3 (CH, C-2), 97.2 (q C, C-11), 55.5 (q C, C-7), 43.7 (CH, C-10), 42.6 (CH2, C-8), 34.6 (CH2, C-12), 31.5 (CH2, C-9), 22.9 (CH3, C-14), 21.5 (CH3, C-15), 13.8 (CH3, C-13).

Isolaurenisol: 2-[3-(Bromomethylene)-1,2-dimethylcyclopentyl]-5-methylphenol ( 2 )

Isolated as a white solid: 2.5 mg; [α] D 20 = −7.2° (c 0.0025, CH3OH); IRνmax 3,513 (O-H), 2,959 (C-H), 2,929, 2,870, 1,616 (C = C), 1,576 (C = C), 1,514, 1,454, 1,412, 1,294 (C-H), 1,254 (C-O), 1,186, 1,123, 809, 787, 653 (C-Br) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 7.9 Hz, 1H, H-5), 6.68 (dd, J = 7.9, 1.0 Hz, 1H, H-4), 6.57 (d, J = 1.1 Hz, 1H, H-2), 5.99 (d, J = 2.0 Hz, 1H, H-13), 5.06 (s, 1H, OH), 3.05 to 2.95 (m, 1H, H-11), 2.56 (dt, J = 12.9, 7.2 Hz, 1H, H-8a), 2.25 (s, 3H, H-15), 2.07 to 1.96 (m, 1H, H-9a), 1.64 to 1.57 (m, 1H, H-8b), 1.45 (s, 3H, H-14), 1.42 to 1.36 (m, 1H, H-9b), 1.22 (d, J = 7.2 Hz, 3H, H-12). 13C NMR (101 MHz, CDCl3) δ 160.2 (q C, C-10), 153.3 (q C, C-1), 138.0 (q C, C-3), 128.7 (q C, C-6), 128.1 (CH, C-5), 121.3 (CH, C-4), 118.2 (CH, C-2), 101.3 (CH, C-13), 52.0 (q C, C-7), 39.2 (CH, C-11), 39.2 (CH2, C-8), 31.0 (CH2, C-9), 26.8 (CH3, H-14), 20.7 (CH3, C-15), 19.1 (CH3, C-12).

Debromoisolaurinterol: [(1 R ,3 S )-1,3-dimethyl-2-methylenecyclopentyl]-5-methyl-2-phenol ( 3 )

Isolated as a colorless oil: ca 1 mg; IRνmax 3,458 (O-H), 3,055 (C-H), 2,984 (C-H), 1,641 (C = C), 1,581 (C = C), 1,113 (C-H) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.0 Hz, 1H, H-5), 6.71 (dd, J = 8.0, 1.1 Hz, 1H, H-4), 6.65 (d, J = 1.4 Hz, 1H, H-2), 5.54 (s, 1H, OH), 5.08 (d, J = 2.1 Hz, 1H, H-12a), 4.93 (d, J = 2.4 Hz, 1H, H-12b), 2.88 to 2.78 (m, 1H, H-10), 2.26 (s, 3H, H-15), 2.25 to 2.18 (m, 1H, H-8a), 2.07 to 1.98 (m, 1H, H-9a), 1.60 to 1.55 (m, 1H, H-8b, obscured), 1.46 (s, 3H, H-14), 1.41 to 1.36 (m, 1H, H-9b), 1.19 (d, J = 7.0 Hz, 3H, H-13).

Debromoaplysinol: 3a-methanol, 1,2,3,8b-Tetrahydro-3,6,8b-trimethylcyclopenta-3 H -[ b ]benzofuran ( 4 )

Isolated as a colorless oil: ca 1 mg; [α] D 20 = 0° (c 0.001, CH3OH); IRνmax 3,425 (O-H), 2,940, 2,871, 1,588 (C = C), 1,499, 1,044 (C-O), 860 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 7.6 Hz, 1H, H-5), 6.66 (dd, J = 7.5, 0.7 Hz, 1H, H-4), 6.57 (s, 1H, H-2), 3.84 (dABq, J = 12.4(AB), 4.3 Hz, 1H, H-12a), 3.71 (dABq, J = 12.4(AB), 8.6 Hz, 1H, H-12b), 2.28 (s, 3H, H-15), 1.88 to 1.78 (m, 2H, H-10, H-8a), 1.72 (dd, J = 8.6, 4.3 Hz, 1H, OH), 1.66 to 1.60 (m, 2H, H-8b, H-9a), 1.46 (s, 3H, H-14), 1.16 to 1.11 (m, 1H, H-9b), 1.08 (d, J = 6.8 Hz, 3H, H-13). 13C NMR (101 MHz, CDCl3) δ 159.1 (q C, C-1), 138.3 (q C, C-3), 133.3 (q C, C-6), 122.2 (CH, C-5), 121.2 (CH, C-4), 109.0 (CH, C-2), 99.6 (q C, C-11), 63.9 (CH2, C-12), 54.2 (q C, C-7), 42.3 (CH, C-10), 42.3 (CH2, C-8), 31.5 (CH2, C-9), 22.9 (CH3, C-14), 21.2 (CH3, C-51), 13.7 (CH3, C-13).

Laur-11-en-10-ol. 3-(4′-Methylphenyl)-1,3,dimethyl-2-methylidenecyclopentanol ( 5 )

Isolated as a colorless oil: ca 1 mg; 1H NMR (600 MHz, CDCl3) δ 7.21 (d, J = 7.9 Hz, 2H, H-1, H-5), 7.07 (d, J = 8.1 Hz, 2H, H-2, H-4), 5.44 (s, 1H, H-12a), 4.99 (s, 1H, H-12b), 3.47 (d, J = 5.9 Hz, 1H, OH), 2.29 (s, 3H, H-15), 2.08 to 2.04 (m, 1H, H-8a), 1.98 to 1.92 (m, 1H, H-8b), 1.82 to 1.77 (m, 1H, H-9a), 1.67 to 1.62 (m, 1H, H-9b, obscured), 1.48 (s, 3H, H-14), 1.36 (s, 3H, H-13). 13C NMR (151 MHz, CDCl3) δ 166.4 (q C, C-11), 145.4 (q C, C-6), 135.3 (q C, C-3), 129.0 (2 ± CH, C-2, C-4), 126.3 (2 ± CH, C-1, C-5), 108.6 (CH2, C-12), 79.3 (q C, C-10), 50.3 (q C, C-7), 39.5 (CH2, C-8), 39.2 (CH2, C-9), 30.8 (CH3, C-14), 28.4 (CH3, C-13), 21.2 (CH3, C-15).

10α-hydroxyldebromoepiaplysin. (−)-2,3,3a,8b-Tetrahydro-3-hydroxy-3,3a,6,8b-tetramethyl-1H-benzocyclopentafuran ( 6 )

Isolated as a colorless oil: ca 1 mg; 1H NMR (600 MHz, CDCl3) δ 6.92 (d, J = 7.6 Hz, 1H, H-5), 6.66 (d, J = 7.4 Hz, 1H, H-4), 6.49 (s, 1H, H-2), 5.35 (bs, 1H, OH), 2.26 (s, 3H, H-15), 2.01 to 1.96 (m, 1H, H-8a, obscured), 1.76 to 1.71 (m, 1H, H-8b, obscured), 1.61 to 1.57 (m, 2H, H-9, obscured), 1.39 (s, 3H, H-13), 1.38 (s, 3H, H-14), 1.28 (s, 3H, H-12). 13C NMR (151 MHz, CDCl3) δ 158.0 (q C, C-1), 138.1 (q C, C-3), 133.5 (q C, C-6), 122.5 (CH, C-5), 121.0 (CH, C-4), 109.6 (CH, C-2), 100.5 (q C, C-11), 82.9 (q C, C-10), 53.6 (q C, C-7), 40.8 (CH2, C-8), 37.0 (CH2, C-9), 23.4 (CH3, C-14), 22.2 (CH3, C-13), 21.1 (CH3, C-15), 14.8 (CH3, C-12).

10-Bromo-3,7,11,11-tetramethylspiro[5.5]undeca-1,7-dien-3-ol ( 7 )

Isolated as a colorless oil: ca 0.1 mg; 1H NMR (600 MHz, CDCl3) δ 5.84 (d, J = 10.4 Hz, 1H, H-4), 5.53 (d, J = 10.5 Hz, 1H, H-5), 5.22 (s, 1H, H-8), 4.63 (dd, J = 10.8, 6.3 Hz, 1H, H-10), 2.65 to 2.59 (m, 1H, H-9a), 2.57 to 2.50 (m, 1H, H-9b), 2.02 to 1.96 (m, 2H, H-1), 1.82 to 1.77 (m, 1H, H-2a), 1.76 to 1.71 (m, 1H, H-2b, obscured), 1.55 (s, 3H, H-14, obscured), 1.29 (s, 3H, H-15), 1.10 (s, 3H, H-13), 1.01 (s, 3H, H-12). 13C NMR (151 MHz, CDCl3) δ 139.0 (q C, C-7), 136.4 (CH, C-4), 131.1 (CH, C-5), 120.7 (CH, C-8), 67.5 (q C, C-3), 61.3 (CH, C-10), 47.1 (q C, C-6), 41.5 (q C, C-11), 36.1 (CH2, C-2), 35.8 (CH2, C-9), 28.6 (CH3, C-15), 28.2 (CH2, C-1), 26.1 (CH3, C-13), 21.7 (CH3, C-14), 17.8 (CH3, C-12).

Additional file

Declarations

Acknowledgements

DZAP gratefully acknowledges scholarship support from the Mexican government (Nacional Councli of Science and Technology (Consejo Nacional de Ciencia y Technologia, CONCYT)) and the University of Newcastle.

Authors’ Affiliations

(1)
Chemistry, School of Environmental and Life Science, The University of Newcastle, University Drive
(2)
Development Technology Department, Interdisciplinary Centre of Marine Sciences, National Technological Institute
(3)
Department of Medical Oncology, Calvary Mater Newcastle Hospital

References

  1. López-Vallejo F, Giulianotti MA, Houghten RA, Medina-Franco JL: Expanding the medicinally relevant chemical space with compound libraries. Drug Dis Today 2012, 17: 718–726. 10.1016/j.drudis.2012.04.001View ArticleGoogle Scholar
  2. Newman DJ, Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75: 311–335. 10.1021/np200906sView ArticleGoogle Scholar
  3. Harvey AL: Natural products in drug discovery. Drug Dis Today 2008, 13: 894–901. 10.1016/j.drudis.2008.07.004View ArticleGoogle Scholar
  4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46: 3–26. 10.1016/S0169-409X(00)00129-0View ArticleGoogle Scholar
  5. Koehn FE, Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Dis 2005, 4: 206–220. 10.1038/nrd1657View ArticleGoogle Scholar
  6. Newman DJ: Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 2008, 51: 2589–2599. 10.1021/jm0704090View ArticleGoogle Scholar
  7. Holland IP, McCluskey A, Sakoff JA, Chau N, Robinson PJ, Motti CA, Wright AD, Van Altena IA: New cytotoxic steroids from an Australian sponge Psammoclema sp. J Nat Prod 2009, 72: 102–106. 10.1021/np800688fView ArticleGoogle Scholar
  8. Wright AD, McCluskey A, Robertson MJ, MacGregor K, Gordon CP, Guenther J: Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical sponge Cymbastela hooperi . Org Biomol Chem 2011, 9: 400–407. 10.1039/c0ob00326cView ArticleGoogle Scholar
  9. Maschek J, Baker B: The chemistry of algal secondary metabolism. In Algal Chemical Ecology. Edited by: Maschek J, Baker B. Springer, Germany; 2008:1–20. Chapter 1 10.1007/978-3-540-74181-7_1View ArticleGoogle Scholar
  10. Eickson KL: Constituents of Laurencia. In Marine Natural Products: Chemical and Biological Perspectives. Edited by: Scheuer PJ. Academic, USA; 1983:131–257. Chapter 4 10.1016/B978-0-12-624005-4.50011-2View ArticleGoogle Scholar
  11. Ji N-Y, Xiao-Ming Li X-M, Lia K, Bin-Gui Wang B-G: Halogenated sesquiterpenes from the marine red alga Laurencia saitoi ( Rhodomelaceae ). Helvet Chim Acta 2009, 92: 1873–1897. 10.1002/hlca.200900073View ArticleGoogle Scholar
  12. Hay ME: Marine chemical ecology: chemical signals and cues structure marine populations, communities, and ecosystems. Annu Rev Mar Sci 2009, 1: 193–212. 10.1146/annurev.marine.010908.163708View ArticleGoogle Scholar
  13. Shui-Chun M, Yue-Wei G: Sesquiterpenes from Chinese red alga Laurencia okamurai . Chin J Nat Med 2010, 8: 321–325.Google Scholar
  14. Crews P, Selover SJ: Comparison the sesquiterpenes from the seaweed Laurencia pacifica and its epiphyte Erythrocystis saccata . Phytochemistry 1986, 25: 1847–1852. 10.1016/S0031-9422(00)81160-7View ArticleGoogle Scholar
  15. Sims JJ, Fenical W, Wing RM, Radlick P: Marine natural products. IV. Prepacifenol, a halogenated epoxy sesquiterpene and precursor to pacifenol from the red alga, Laurencia filiformis. J Am Chem Soc 1973, 95: 972–972. 10.1021/ja00784a083View ArticleGoogle Scholar
  16. Sims JJ, Donnell MS, Leary JV, Lacy GH: Antimicrobial agents from marine algae. Antimicrob Agents Chemother 1975, 7: 320–321. 10.1128/AAC.7.3.320View ArticleGoogle Scholar
  17. Dembitsky VM, Gloriozova TA, Poroikov VV: Natural peroxy anticancer agents. Mini-Rev Med Chem 2007, 7: 571–589. 10.2174/138955707780859396View ArticleGoogle Scholar
  18. Sun J, Shi D, Ma M, Li S, Wang S, Han L, Yang Y, Fan X, Shi J, He L: Sesquiterpenes from the red alga Laurencia tristicha. J Nat Prod 2005, 68: 915–919. 10.1021/np050096gView ArticleGoogle Scholar
  19. Sun J, Shi D, Li S, Wang S, Han L, Fan X, Yang Y, Shi J: Chemical constituents of the red alga Laurencia triticha . J Asian Nat Prod Res 2007, 9: 725–734. 10.1080/10286020601103338View ArticleGoogle Scholar
  20. Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A: Synthesis and biological activity of Δ-5,6-norcantharimides: importance of the 5,6-bridge. Eur J Med Chem 2010, 45: 1717–1723. 10.1016/j.ejmech.2010.01.004View ArticleGoogle Scholar
  21. Suzuki M, Kurosawa E: New aromatic sesquiterpenoids from the red alga Laurencia Okamurai yamada. Tetrahedron Lett 1978, 28: 2503–2506.Google Scholar
  22. Suziki M, Kurata K, Kurosawa E: The structure of isoaplysin, a brominated rearranged cuparane-type sesquiterpenoid from the red alga Laurencia okamurai Yamada. Bull Chem Soc Jpn 1986, 59: 3981–3982. 10.1246/bcsj.59.3981View ArticleGoogle Scholar
  23. Harrowven DC, Lucas MC, Howes PD: The synthesis of a natural product family: from debromoisoluaurinterol to the aplysins. Tetrahedron 2001, 57: 791–804. 10.1016/S0040-4020(00)01055-3View ArticleGoogle Scholar
  24. Blunt JW, Lake RJ, Munro MHG: Sesquiterpenes from the marine red alga Laurencia distichophylla . Phytochemistry 1984, 23: 1951–1954. 10.1016/S0031-9422(00)84948-1View ArticleGoogle Scholar
  25. Yamada K, Yazawa H, Uemura D, Toda M, Hirata Y: Total synthesis of (±)aplysin and (±)debromoaplysin. Tetrahedron 1969, 25: 3509–3520. 10.1016/S0040-4020(01)82886-6View ArticleGoogle Scholar
  26. Li X-D, Miao F-P, Li K, Ji N-Y: Sesquiterpenes and acetogenins from the marine red alga Laurencia okamurai . Fitoterapia 2012, 83: 518–522. 10.1016/j.fitote.2011.12.018View ArticleGoogle Scholar
  27. Davyt D, Fernandez R, Suescun L, Mombrú AW, Saldaña J, Domínguez L, Coll J, Fujii MT, Manta E: New sesquiterpene derivatives from the red alga Laurencia scoparia : isolation, structure determination, and anthelmintic activity. J Nat Prod 2001, 64: 1552–1555. 10.1021/np0102307View ArticleGoogle Scholar
  28. König GM, Wright AD: Laurencia rigida : chemical investigation of its antifouling dichloromethane extract. J Nat Prod 1997, 60: 967–970. 10.1021/np970181rView ArticleGoogle Scholar
  29. Suescun L, Mombrú AW, Mariezcurrena RA, Davyt D, Fernandez R, Manta E: Two natural products from the alga Laurencia scoparia . Acta Cryst Section C 2001, C57: 286–288. 10.1107/S0108270100017935View ArticleGoogle Scholar
  30. Kelman D, Wright AD: The importance of 1 H-nuclear magnetic resonance spectroscopy for reference standard validation in analytical sciences. PLoS One 2012, 7: e42061. 10.1371/journal.pone.0042061View ArticleGoogle Scholar
  31. Leeson PD, Springthorpe B: The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Dis 2007, 6: 881–890. 10.1038/nrd2445View ArticleGoogle Scholar
  32. Harwood LM: Dry-column flash chromatography. Aldrichimica Acta 1985, 18: 25–26.Google Scholar

Copyright

© Zaleta-Pinet et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.